Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 high-pathogenicity avian influenza virus with reduced adverse reactions.
Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, Kawahara E, Senpuku K, Shimooka M, Quynh Mai LT, Suzuki R, Nogimori T, Yamamoto T, Hirai T, Kato T, Watanabe T, Akita H, Yoshioka Y.
Kawai A, et al. Among authors: suzuki r.
Mol Ther. 2024 Dec 17:S1525-0016(24)00831-1. doi: 10.1016/j.ymthe.2024.12.032. Online ahead of print.
Mol Ther. 2024.
PMID: 39690742
Free article.